Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ1,41
KB0,15
PKN77,1477,2-0,36
Msft475,54475,6-0,70
Nokia4,4514,699-1,91
IBM277,79277,91-1,11
Mercedes-Benz Group AG50,750,72-1,63
PFE24,7124,72-0,48
13.06.2025 19:39:54
Indexy online
AD Index online
select
AD Index online
 

  • 02.06.2025 16:28:20
Teva (TEVJF.PK, US Other OTC (Pink Sheets))
Poslední obchod Změna (%) Změna (USD) Objem obchodů (ks)
15,56 -12,58 -2,24 1
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 13.06.2025
Popis společnosti
Obecné informace
Název společnostiTeva Pharmaceutical Industries Ltd
TickerTEVA
Kmenové akcie:Ordinary Shares
RICTEVA.TA
ISINIL0006290147
Prioritní akciePreferred Shares
Poslední známé roční výsledky31.12.2024
Poslední známé čtvrtletní výsledky31.03.2025
Počet zaměstnanců k 31.03.2025 37 000
Akcie v oběhu k 14.05.20251 146 838 689
MěnaUSD
Kontaktní informace
Ulice124 Dvora Hanevi'a St.
MěstoTEL AVIV-YAFO
PSČ6944020
ZeměIsrael
Kontatní osobaRan Meir
Funkce kontaktní osobySenior Vice President, Global Head of Investor Relations and Corporate Communications
Telefon97 239 148 213
Fax97239234050
Kontatní telefon12 674 684 475

Business Summary: Teva Pharmaceutical Industries Ltd is a Israeli-based pharmaceutical company. The Company operates through three segments: North America, Europe and International Markets. Each business segment manages entire product portfolio in its region, including generics, specialty and over-the-counter (OTC) products. In addition to these three segments, The Company has other activities, primarily the sale of active pharmaceutical ingredients (API) to third parties, certain contract manufacturing services and an out-licensing platform offering a portfolio of products to other pharmaceutical companies through its affiliate Medis.
Financial Summary: BRIEF: For the three months ended 31 March 2025, Teva Pharmaceutical Industries Ltd revenues increased 2% to $3.89B. Net income totaled $214M vs. loss of $139M. Revenues reflect United States segment increase of 11% to $1.91B, United States segment increase of 11% to $1.91B. Net Income reflects United States segment income increase of 52% to $532M, Other segment income totaling $13M vs. loss of $2M.
Odvětvová klasifikace
TRBC2012Pharmaceuticals (NEC)
RBSS2004Pharmaceuticals - Diversified
MGINDUSTRYBiotechnology & Drugs
MGSECTORHealthcare
NAICSPharmaceutical Preparation Manufacturing
NAICSBiological Product (except Diagnostic) Manufacturing
NAICSMedicinal and Botanical Manufacturing
NAICSResearch and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
NAICS2007Pharmaceutical Preparation Mfg
NAICS2007Biological Product (exc Diagnostic) Mfg
NAICS2007Medicinal & Botanical Mfg
NAICS2007Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
NAICS1997Pharmaceutical Preparation Manufacturing
NAICS1997Biological Product (except Diagnostic) Manufacturing
NAICS1997Medicinal and Botanical Manufacturing
NAICS1997Research and Development in the Physical, Engineering, and Life Sciences
SICPharmaceutical Preparations
SICBiological Prod's Not Diagnostic
SICMedicinals And Botanicals
SICCommercial Physical Research



  • Poslední aktualizace: 13.06.2025
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
President, Chief Executive Officer, DirectorRichard Francis5601.01.202301.01.2023
Chief Financial Officer, Executive Vice PresidentEliyahu Kalif5222.12.201922.12.2019
Executive Vice President, Chief Human Resources OfficerPlacid Jover44
Executive Vice President - European CommercialRichard Daniell5827.11.201727.11.2017
Executive Vice President - U.S. CommercialChristine Fox5717.11.202317.11.2023
Executive Vice President - Global R & D, Chief Medical OfficerEric Hughes55
Executive Vice President - Business DevelopmentEvan Lippman5631.03.202531.03.2025
Executive Vice President, Chief Legal OfficerDavid McAvoy62
Executive Vice President - International Markets CommercialMark Sabag5415.08.2021
Executive Vice President - Teva Global OperationsMatthew Shields5103.06.202403.06.2024